跳到正文
原文
Nature 健康护理主题·· 3 天前AI 评分53

早发乳腺癌全球现状:从风险评估到精准预防与癌症拦截

Global landscape of early-onset breast cancer: from understanding risk to precision prevention and cancer interception

AI 导读

本文综述早发乳腺癌的全球负担、风险因素、遗传检测与精准预防策略。研究指出早发乳腺癌在发病率、分子亚型分布及生存率上与老年患者存在差异,BRCA1/2及其他易感基因突变检出率较高,建议结合多基因风险评分和循环肿瘤DNA(ctDNA)进行个体化风险分层与微小残留病监测,以提升早期筛查与干预效果。

正文
  1. Kim, J. et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat. Med. 31, 1154–1162 https://doi.org/10.1038/s41591-025-03502-3 (2025).

    Article  CAS  PubMed  Google Scholar 

  2. Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 https://doi.org/10.3322/caac.21834 (2024).

    Article  PubMed  Google Scholar 

  3. Sung, H. et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J. Clin. 76, e70090 https://doi.org/10.3322/caac.70090 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Li, N. H. Y. & Li, C. I. Incidence rate trends of breast cancer overall and by molecular subtype by race and ethnicity and age. JAMA Netw. Open 8, e2456142 https://doi.org/10.1001/jamanetworkopen.2024.56142 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Gupta, A. & Akinyemiju, T. Early-onset cancer incidence in the United States by race/ethnicity between 2011 and 2020. Cancer Epidemiol. 92, 102632 https://doi.org/10.1016/j.canep.2024.102632 (2024).

    Article  PubMed  Google Scholar 

  6. Humlevik, R. O. C. et al. Distinct clinicopathological features and treatment differences in breast cancer patients of young age. Sci. Rep. 15, 5655 https://doi.org/10.1038/s41598-025-90053-9 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Santucci, C. et al. Trends in cancer mortality under age 50 in 15 upper-middle and high-income countries. J. Natl Cancer Inst. 117, 747–760 https://doi.org/10.1093/jnci/djae288 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Jayasekera, J. et al. Breast cancer mortality by age and race and/or ethnicity across counties in the United States, 2000-2019. J. Natl Cancer Inst. 118, 1705–1714 https://doi.org/10.1093/jnci/djag103 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Patel, V. R., Adamson, A. S. & Welch, H. G. The rise in early-onset cancer in the US population — more apparent than real. JAMA Intern. Med. 185, 1370–1374 https://doi.org/10.1001/jamainternmed.2025.4917 (2025).

    Article  PubMed  Google Scholar 

  10. Xu, S., Murtagh, S., Han, Y., Wan, F. & Toriola, A. T. Breast cancer incidence among US women aged 20 to 49 years by race, stage, and hormone receptor status. JAMA Netw. Open 7, e2353331 https://doi.org/10.1001/jamanetworkopen.2023.53331 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Galukande, M. et al. Maternally orphaned children and intergenerational concerns associated with breast cancer deaths among women in sub-Saharan Africa. JAMA Oncol. 7, 285–289 https://doi.org/10.1001/jamaoncol.2020.6583 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  12. Guida, F. et al. Global and regional estimates of orphans attributed to maternal cancer mortality in 2020. Nat. Med. 28, 2563–2572 https://doi.org/10.1038/s41591-022-02109-2 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Bedrosian, I. et al. Germline testing in patients with breast cancer: ASCO–Society of Surgical Oncology Guideline. J. Clin. Oncol. 42, 584–604 https://doi.org/10.1200/jco.23.02225 (2024).

    Article  PubMed  Google Scholar 

  14. Roberts, E., Howell, S. & Evans, D. G. Polygenic risk scores and breast cancer risk prediction. Breast 67, 71–77 https://doi.org/10.1016/j.breast.2023.01.003 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  15. Lamb, L. R., Mercaldo, S. F., Carney, A. & Lehman, C. D. A deep learning breast cancer risk model for precise supplemental screening. JAMA Netw. Open 9, e2610559 https://doi.org/10.1001/jamanetworkopen.2026.10559 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  16. Brantley, K. D. et al. Tumor genomics in patients younger than 40 years of age with metastatic breast cancer. NPJ Precis. Oncol. 10, 144 https://doi.org/10.1038/s41698-026-01333-0 (2026).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Reid, S., Spalluto, L. & Pal, T. Breast cancer risk stratification in Black women: current status and potential solutions to improve accuracy. J. Natl Compr. Canc Netw. 24, e257079 https://doi.org/10.6004/jnccn.2025.7079 (2025).

    Article  CAS  PubMed  Google Scholar 

  18. Lambertini, M. et al. Clinical behavior of breast cancer in young BRCA carriers and prediagnostic awareness of germline BRCA status. J. Clin. Oncol. 43, 1706–1719 https://doi.org/10.1200/JCO-24-01334 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Piccart, M. et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 22, 476–488 https://doi.org/10.1016/S1470-2045(21)00007-3 (2021).

    Article  CAS  PubMed  Google Scholar 

  20. Schlam, I., Tolaney, S. M., Lin, N. U., Parsons, H. & Morganti, S. Circulating tumor DNA in early breast cancer. JAMA Oncol. 12, 773–784 https://doi.org/10.1001/jamaoncol.2026.1465 (2026).

    Article  PubMed  Google Scholar 

  21. Sisca, L. et al. Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis. Breast Cancer Res. Treat. 216, 16 https://doi.org/10.1007/s10549-026-07919-3 (2026).

    Article  CAS  PubMed  Google Scholar 

  22. Hunter, N. B. et al. The pathologic response evaluation and detection in circulating tumor-DNA study: ultrasensitive circulating tumor-DNA assessment of breast cancer minimal residual disease. J. Clin. Oncol. 44, 1283–1295 https://doi.org/10.1200/JCO-25-02934 (2026).

    Article  CAS  PubMed  Google Scholar 

  23. Medford, A. J. et al. Molecular residual disease in breast cancer: detection and therapeutic interception. Clin. Cancer Res. 29, 4540–4548 https://doi.org/10.1158/1078-0432.CCR-23-0757 (2023).

    Article  CAS  PubMed  Google Scholar 

  24. Di Cosimo, S. et al. Circulating tumor DNA in early breast cancer: evidence, challenges, next steps. Cancer 132, e70521 https://doi.org/10.1002/cncr.70521 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  25. Cohen, S. A., Liu, M. C. & Aleshin, A. Practical recommendations for using ctDNA in clinical decision making. Nature 619, 259–268 https://doi.org/10.1038/s41586-023-06225-y (2023).

    Article  CAS  PubMed  Google Scholar 

  26. Villarreal-Garza, C. et al. Clinical utility of genomic signatures in young breast cancer patients: a systematic review. NPJ Breast Cancer 6, 46 https://doi.org/10.1038/s41523-020-00188-3 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  27. Lobo-Martins, S., Luen, S. J., Piccart, M. & Loi, S. Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer. Nat. Rev. Clin. Oncol. 23, 297–315 https://doi.org/10.1038/s41571-026-01120-7 (2026).

    Article  CAS  PubMed  Google Scholar 

  28. Licata, L. et al. Real-world use of multigene signatures in early breast cancer: differences to clinical trials. Breast Cancer Res. Treat. 205, 39–48 https://doi.org/10.1007/s10549-023-07227-0 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Wang, W. et al. Global, regional, and national burden of breast cancer in young women from 1990 to 2021: findings from the Global Burden of Disease Study 2021. BMC Cancer 25, 1015 https://doi.org/10.1186/s12885-025-14416-1 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  30. Global Burden of Disease Study Collaborators. Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Oncol. 27, 302–326 https://doi.org/10.1016/S1470-2045(25)00730-2 (2026).

    Article  Google Scholar 

  31. Cai, Y., Dai, F., Ye, Y. & Qian, J. The global burden of breast cancer among women of reproductive age: a comprehensive analysis. Sci. Rep. 15, 9347 https://doi.org/10.1038/s41598-025-93883-9 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Valencia, O. M. et al. The role of genetic testing in patients with breast cancer: a review. JAMA Surg. 152, 589–594 https://doi.org/10.1001/jamasurg.2017.0552 (2017).

    Article  PubMed  Google Scholar 

  33. Acheampong, T., Kehm, R. D., Terry, M. B., Argov, E. L. & Tehranifar, P. Incidence trends of breast cancer molecular subtypes by age and race/ethnicity in the US from 2010 to 2016. JAMA Netw. Open 3, e2013226 https://doi.org/10.1001/jamanetworkopen.2020.13226 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  34. Walsh, T. et al. Genetic predisposition to breast cancer due to mutations other than BRCA1 and BRCA2 founder alleles among Ashkenazi Jewish women. JAMA Oncol. 3, 1647–1653 https://doi.org/10.1001/jamaoncol.2017.1996 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  35. Lipsyc-Sharf, M. et al. Age, body mass index, tumor subtype, and racial and ethnic disparities in breast cancer survival. JAMA Netw. Open 6, e2339584 https://doi.org/10.1001/jamanetworkopen.2023.39584 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  36. Patel, V. R., Adamson, A. S. & Welch, H. G. The rise in early-onset cancer in the US population-more apparent than real. JAMA Intern. Med. 185, 1370–1374 https://doi.org/10.1001/jamainternmed.2025.4917 (2025).

    Article  PubMed  Google Scholar 

  37. Shi, M. et al. Accelerating discovery of cancer causes for prevention in the era of rising early-onset cancers. Cell 189, 2232–2253 https://doi.org/10.1016/j.cell.2026.03.019 (2026).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ugai, T. et al. Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nat. Rev. Clin. Oncol. 19, 656–673 https://doi.org/10.1038/s41571-022-00672-8 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  39. Giaquinto, A. N. et al. Breast cancer statistics 2024. CA Cancer J. Clin. 74, 477–495 https://doi.org/10.3322/caac.21863 (2024).

    Article  PubMed  Google Scholar 

  40. Caswell-Jin, J. L. et al. Analysis of breast cancer mortality in the US-1975 to 2019. JAMA 331, 233–241 https://doi.org/10.1001/jama.2023.25881 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  41. Hendrick, R. E., Helvie, M. A. & Monticciolo, D. L. Breast cancer mortality rates have stopped declining in U.S. women younger than 40 years. Radiology 299, 143–149 https://doi.org/10.1148/radiol.2021203476 (2021).

    Article  PubMed  Google Scholar 

  42. Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10–45 https://doi.org/10.3322/caac.21871 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  43. Gu, H. et al. Global burden and trends of breast cancer: GLOBOCAN 2022 estimates of incidence and mortality in 185 countries. Chin. Med. J. 139, 404–414 https://doi.org/10.1097/CM9.0000000000003921 (2026).

    Article  PubMed  Google Scholar 

  44. Sharma, R. Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018. Breast Cancer Res. Treat. 187, 557–567 https://doi.org/10.1007/s10549-020-06083-6 (2021).

    Article  PubMed  Google Scholar 

  45. National Cancer Institute. SEER*Explorer: An interactive website for SEER cancer statistics https://seer.cancer.gov/statistics-network/explorer/ (2026).

  46. Sopik, V. International variation in breast cancer incidence and mortality in young women. Breast Cancer Res. Treat. 186, 497–507 https://doi.org/10.1007/s10549-020-06003-8 (2021).

    Article  CAS  PubMed  Google Scholar 

  47. Girardi, F. et al. Global breast cancer survival estimates in 2017-2021 to advance the WHO Global Breast Cancer Initiative. Nat. Med. 32, 3313–3321 https://doi.org/10.1038/s41591-026-04531-2 (2026).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Hoskins, K. F. et al. Association of social determinants and tumor biology with racial disparity in survival from early-stage, hormone-dependent breast cancer. JAMA Oncol. 9, 536–545 https://doi.org/10.1001/jamaoncol.2022.7705 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  49. Hoskins, K. F., Danciu, O. C., Ko, N. Y. & Calip, G. S. Association of race/ethnicity and the 21-gene recurrence score with breast cancer-specific mortality among US women. JAMA Oncol. 7, 370–378 https://doi.org/10.1001/jamaoncol.2020.7320 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  50. Giaquinto, A. N. et al. Breast cancer statistics, 2022. CA Cancer J. Clin. 72, 524–541 https://doi.org/10.3322/caac.21754 (2022).

    Article  PubMed  Google Scholar 

  51. Thorn, G. J. et al. The clinical and molecular landscape of breast cancer in women of African and South Asian ancestry. Nat. Commun. 16, 4237 https://doi.org/10.1038/s41467-025-59144-z (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Abdou, Y. et al. Prognostic and predictive insights from genomic assays for breast cancer in diverse populations: a review. JAMA Oncol. 11, 655–663 https://doi.org/10.1001/jamaoncol.2025.0178 (2025).

    Article  PubMed  Google Scholar 

  53. Howlader, N. et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J. Natl Cancer Inst. 106, dju055 https://doi.org/10.1093/jnci/dju055 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  54. Vrancken Peeters, N. et al. Five-year conditional relative survival up to 10 years post-diagnosis among adolescent and young adult breast cancer patients by age, stage, and receptor subtype. J. Natl Cancer Cent. 5, 297–305 https://doi.org/10.1016/j.jncc.2025.01.005 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  55. Khongthong, P., Prateepchaiboon, T. & Ruangsuwan, T. Overall survival and prognostic factors in young women with breast cancer: a retrospective cohort study from Southern Thailand. World J. Surg. Oncol. 24, 229 https://doi.org/10.1186/s12957-026-04349-9 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  56. Thomas, A. et al. Incidence and survival by human epidermal growth factor receptor 2 status in young women with stage I-III breast cancer: SEER, 2010-2016. Clin. Breast Cancer 20, e410–e422 https://doi.org/10.1016/j.clbc.2020.01.014 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Avila, J. et al. Stage IV breast cancer incidence and survival, 2010-2021. JAMA Netw. Open 9, e2612042 https://doi.org/10.1001/jamanetworkopen.2026.12042 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  58. El Saghir, N. S. et al. Improved survival of young patients with breast cancer 40 years and younger at diagnosis. JCO Glob. Oncol. 9, e2200354 https://doi.org/10.1200/GO.22.00354 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  59. Mallet, A. et al. Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer. Ther. Adv. Med. Oncol. 14, 17588359211070362 https://doi.org/10.1177/17588359211070362 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Svanoe, A. A. et al. Age-related phenotypes in breast cancer: a population-based study. Int. J. Cancer 154, 2014–2024 https://doi.org/10.1002/ijc.34863 (2024).

    Article  CAS  PubMed  Google Scholar 

  61. Easton, D. F. et al. Gene-panel sequencing and the prediction of breast-cancer risk. N. Engl. J. Med. 372, 2243–2257 https://doi.org/10.1056/NEJMsr1501341 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402–2416 https://doi.org/10.1001/jama.2017.7112 (2017).

    Article  CAS  PubMed  Google Scholar 

  63. Breast Cancer Association Consortium et al. Breast cancer risk genes — association analysis in more than 113,000 women. N. Engl. J. Med. 384, 428–439 https://doi.org/10.1056/NEJMoa1913948 (2021).

    Article  Google Scholar 

  64. Heeke, A. L. et al. The genomic landscape of breast cancer in young and older women. Clin. Breast Cancer 24, 630–638.e3 https://doi.org/10.1016/j.clbc.2024.07.008 (2024).

    Article  CAS  PubMed  Google Scholar 

  65. Apostolou, P. et al. Genetic testing of breast cancer patients with very early-onset breast cancer (≤30 years) yields a high rate of germline pathogenic variants, mainly in the BRCA1, TP53, and BRCA2 genes. Cancers 16, 2368 https://doi.org/10.3390/cancers16132368 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Evans, D. G. et al. High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer. J. Med. Genet. 59, 115–121 https://doi.org/10.1136/jmedgenet-2020-107347 (2022).

    Article  CAS  PubMed  Google Scholar 

  67. Daly, M. B. et al. The association between age at breast cancer diagnosis and prevalence of pathogenic variants. Breast Cancer Res. Treat. 199, 617–626 https://doi.org/10.1007/s10549-023-06946-8 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Breast Cancer Association Consortium et al. Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes. JAMA Oncol. 8, e216744 https://doi.org/10.1001/jamaoncol.2021.6744 (2022).

    Article  Google Scholar 

  69. Lalloo, F. et al. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur. J. Cancer 42, 1143–1150 https://doi.org/10.1016/j.ejca.2005.11.032 (2006).

    Article  CAS  PubMed  Google Scholar 

  70. Waks, A. G. et al. Somatic and germline genomic alterations in very young women with breast cancer. Clin. Cancer Res. 28, 2339–2348 https://doi.org/10.1158/1078-0432.CCR-21-2572 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Isiklar, A. D., Aliyeva, L., Yesilyurt, A., Soyder, A. & Basaran, G. Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients. Breast Cancer Res. Treat. 202, 297–304 https://doi.org/10.1007/s10549-023-07074-z (2023).

    Article  CAS  PubMed  Google Scholar 

  72. de Andrade, K. C. et al. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. Lancet Oncol. 22, 1787–1798 https://doi.org/10.1016/S1470-2045(21)00580-5 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  73. Yang, X. et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J. Clin. Oncol. 38, 674–685 https://doi.org/10.1200/JCO.19.01907 (2020).

    Article  CAS  PubMed  Google Scholar 

  74. Hu, C. et al. A population-based study of genes previously implicated in breast cancer. N. Engl. J. Med. 384, 440–451 https://doi.org/10.1056/NEJMoa2005936 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  75. Zang, F. et al. Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype. Breast Cancer Res. Treat. 195, 431–439 https://doi.org/10.1007/s10549-022-06702-4 (2022).

    Article  CAS  PubMed  Google Scholar 

  76. Papadopoulou, E. et al. Germline genetic testing in breast and gynecologic cancers: evaluating age at diagnosis as a determinant. Cancers 18, 1541 https://doi.org/10.3390/cancers18101541 (2026).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Momozawa, Y. et al. Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat. Commun. 9, 4083 https://doi.org/10.1038/s41467-018-06581-8 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Kratz, C. P. et al. Urgent need to recognize that disease-causing TP53 variants with atypical penetrance require distinct clinical recommendations. J. Natl Cancer Inst. https://doi.org/10.1093/jnci/djag015 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  79. Tischkowitz, M. et al. Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 23, 1416–1423 https://doi.org/10.1038/s41436-021-01151-8 (2021).

    Article  PubMed  Google Scholar 

  80. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate (National Comprehensive Cancer Network, 2026).

  81. Pal, T. et al. Consideration of inherited cancer risk on a continuum: an international and multidisciplinary perspective: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 28, 101659 https://doi.org/10.1016/j.gim.2025.101659 (2026).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Metcalfe, K. et al. Frequency of germline pathogenic variants in breast cancer predisposing genes in a national cohort of young women with breast cancer. Br. J. Cancer 135, 917–923 https://doi.org/10.1038/s41416-026-03502-1 (2026).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Schmidt, M. K. et al. Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers. J. Clin. Oncol. 34, 2750–2760 https://doi.org/10.1200/jco.2016.66.5844 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Thomas, C. E. & Peters, U. Genomic landscape of cancer in racially and ethnically diverse populations. Nat. Rev. Genet. 26, 336–349 https://doi.org/10.1038/s41576-024-00796-w (2025).

    Article  CAS  PubMed  Google Scholar 

  85. Mortimer, J. E. et al. Prevalence of BRCA1 and BRCA2 variants in an unselected population of women with breast cancer. JAMA Netw. Open 8, e2531577 https://doi.org/10.1001/jamanetworkopen.2025.31577 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  86. Yap, Y. S. et al. Insights into breast cancer in the east vs the west: a review. JAMA Oncol. 5, 1489–1496 https://doi.org/10.1001/jamaoncol.2019.0620 (2019).

    Article  PubMed  Google Scholar 

  87. Fergus, K. B. et al. Germline pathogenic variants among women without a history of breast cancer: a secondary analysis of the WISDOM randomized clinical trial. JAMA Intern. Med. https://doi.org/10.1001/jamainternmed.2025.7323 (2025).

    Article  Google Scholar 

  88. Domchek, S. M. et al. Comparison of the prevalence of pathogenic variants in cancer susceptibility genes in Black women and non-hispanic white women with breast cancer in the United States. JAMA Oncol. 7, 1045–1050 https://doi.org/10.1001/jamaoncol.2021.1492 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  89. Palmer, J. R. et al. Contribution of germline predisposition gene mutations to breast cancer risk in African American women. J. Natl Cancer Inst. 112, 1213–1221 https://doi.org/10.1093/jnci/djaa040 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Abul-Husn, N. S. et al. Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank. Genome Med. 12, 2 https://doi.org/10.1186/s13073-019-0691-1 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Amin, S. et al. Frequency and spectrum of BRCA pathogenic/likely pathogenic variants in the Hispanic population of South Florida: a retrospective analysis. J. Clin. Oncol. 43, 10579–10579 https://doi.org/10.1200/JCO.2025.43.16_suppl.10579 (2025).

    Article  Google Scholar 

  92. Yadav, S. et al. Racial and ethnic differences in multigene hereditary cancer panel test results for women with breast cancer. J. Natl Cancer Inst. 113, 1429–1433 https://doi.org/10.1093/jnci/djaa167 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Lieberman, S. et al. Common founder BRCA2 pathogenic variants and breast cancer characteristics in Ethiopian Jews. Breast Cancer Res. Treat. 193, 217–224 https://doi.org/10.1007/s10549-022-06557-9 (2022).

    Article  CAS  PubMed  Google Scholar 

  94. Ludman, M. D., Philipsborn, S. L., Hartmajer, S., Shwartzman, N. S. & Reinstein, E. Recurring pathogenic variants in the BRCA2 gene in the Ethiopian Jewish population. Founder mutations? Fam. Cancer 21, 121–123 https://doi.org/10.1007/s10689-021-00255-z (2022).

    Article  CAS  PubMed  Google Scholar 

  95. Friebel, T. M. et al. BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Hum. Mutat. 40, 1781–1796 https://doi.org/10.1002/humu.23804 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  96. Rebbeck, T. R. et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum. Mutat. 39, 593–620 https://doi.org/10.1002/humu.23406 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Nguyen, T. et al. Equity in cancer genomics in the UK: a cross-sectional analysis of a national cancer cohort. Lancet Oncol. 26, 971–980 https://doi.org/10.1016/S1470-2045(25)00199-8 (2025).

    Article  CAS  PubMed  Google Scholar 

  98. Lao, O. et al. Correlation between genetic and geographic structure in Europe. Curr. Biol. 18, 1241–1248 https://doi.org/10.1016/j.cub.2008.07.049 (2008).

    Article  CAS  PubMed  Google Scholar 

  99. Tian, C. et al. Analysis and application of European genetic substructure using 300 K SNP information. PLoS Genet. 4, e4 https://doi.org/10.1371/journal.pgen.0040004 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Seldin, M. F. et al. European population substructure: clustering of northern and southern populations. PLoS Genet. 2, e143 https://doi.org/10.1371/journal.pgen.0020143 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. HUGO Pan-Asian SNP Consortium et al. Mapping human genetic diversity in Asia. Science 326, 1541–1545 https://doi.org/10.1126/science.1177074 (2009).

    Article  CAS  Google Scholar 

  102. Anders, C. K. et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J. Clin. Oncol. 26, 3324–3330 https://doi.org/10.1200/JCO.2007.14.2471 (2008).

    Article  PubMed  Google Scholar 

  103. Plichta, J. K. et al. Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age. Breast Cancer Res. Treat. 180, 227–235 https://doi.org/10.1007/s10549-020-05542-4 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Davis Lynn, B. C. et al. Breast cancer incidence rates in Ghanaian and US Black women from 2013 through 2015. JAMA Netw. Open 8, e2537160 https://doi.org/10.1001/jamanetworkopen.2025.37160 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  105. US Preventive Services Task Force et al. Screening for breast cancer: US Preventive Services Task Force Recommendation Statement. JAMA 331, 1918–1930 https://doi.org/10.1001/jama.2024.5534 (2024).

    Article  Google Scholar 

  106. American Cancer Society. Breast Cancer Facts & Figures 2024–2025 (American Cancer Society, 2024).

  107. Cho, B. et al. Evaluation of racial/ethnic differences in treatment and mortality among women with triple-negative breast cancer. JAMA Oncol. 7, 1016–1023 https://doi.org/10.1001/jamaoncol.2021.1254 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  108. Newman, L. Oncologic anthropology: global variations in breast cancer risk, biology, and outcome. J. Surg. Oncol. 128, 959–966 https://doi.org/10.1002/jso.27459 (2023).

    Article  PubMed  Google Scholar 

  109. Chauvin, P., Huet, T., Gligorov, J. & Sargent, C. Social disparities in the frequency and severity of triple-negative breast cancer at diagnosis in a university hospital in Paris, France: confronting race and ethnic blindness. PLoS ONE 21, e0349041 https://doi.org/10.1371/journal.pone.0349041 (2026).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Arora, K. et al. Genetic ancestry-based differences in biomarker-based eligibility for precision oncology therapies. JAMA Oncol. 11, 310–316 https://doi.org/10.1001/jamaoncol.2024.5794 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  111. Davis, M. B. & Martini, R. Precision oncology and genetic ancestry: the science behind population-based cancer disparities. Cancer Cell 43, 619–622 https://doi.org/10.1016/j.ccell.2025.03.022 (2025).

    Article  CAS  PubMed  Google Scholar 

  112. Garcia-Cardenas, J. M. et al. Toward equitable precision oncology: monitoring racial and ethnic inclusion in genomics and clinical trials. JCO Precis. Oncol. 8, e2300398 https://doi.org/10.1200/PO.23.00398 (2024).

    Article  PubMed  Google Scholar 

  113. Telonis, A. G., Rodriguez, D. A., Spanheimer, P. M., Figueroa, M. E. & Goel, N. Genetic ancestry-specific molecular and survival differences in admixed patients with breast cancer. Ann. Surg. 279, 866–873 https://doi.org/10.1097/SLA.0000000000006135 (2024).

    Article  PubMed  Google Scholar 

  114. Goel, N. et al. Translational epidemiology: an integrative approach to determine the interplay between genetic ancestry and neighborhood socioeconomic status on triple negative breast cancer. Ann. Surg. 276, 430–440 https://doi.org/10.1097/SLA.0000000000005554 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  115. Chatzipanagiotou, O. P. et al. Genetic ancestry and colorectal cancer in the All of Us dataset. JAMA Netw. Open 9, e2628789 https://doi.org/10.1001/jamanetworkopen.2026.28789 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  116. Tolentino-Rodriguez, L. et al. Breast cancer characteristics in low- and middle-income countries: an umbrella review. Cancer Epidemiol. 96, 102797 https://doi.org/10.1016/j.canep.2025.102797 (2025).

    Article  PubMed  Google Scholar 

  117. Torres, D. et al. Interaction between genetic ancestry and common breast cancer susceptibility variants in Colombian women. Int. J. Cancer 144, 2181–2191 https://doi.org/10.1002/ijc.32023 (2019).

    Article  CAS  PubMed  Google Scholar 

  118. Slattery, M. L. et al. Genetic variation in genes involved in hormones, inflammation and energetic factors and breast cancer risk in an admixed population. Carcinogenesis 33, 1512–1521 https://doi.org/10.1093/carcin/bgs163 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Churpek, J. E. et al. Inherited predisposition to breast cancer among African American women. Breast Cancer Res. Treat. 149, 31–39 https://doi.org/10.1007/s10549-014-3195-0 (2015).

    Article  CAS  PubMed  Google Scholar 

  120. Manirakiza, A. V. C., Mutesa, L., Mathew, C. G. & Olopade, O. I. Breast cancer: genetic risk assessment, diagnostics, and therapeutics in African populations. Annu. Rev. Genomics Hum. Genet. 26, 245–259 https://doi.org/10.1146/annurev-genom-111522-013953 (2025).

    Article  CAS  PubMed  Google Scholar 

  121. Jiagge, E. et al. Comparative analysis of breast cancer phenotypes in African American, White American, and West versus East African patients: correlation between African ancestry and triple-negative breast cancer. Ann. Surg. Oncol. 23, 3843–3849 https://doi.org/10.1245/s10434-016-5420-z (2016).

    Article  PubMed  Google Scholar 

  122. Paixao, D. et al. Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients. Front. Oncol. 12, 976959 https://doi.org/10.3389/fonc.2022.976959 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Miyashita, M. et al. Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Res. 25, 58 https://doi.org/10.1186/s13058-023-01627-2 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Jia, G. et al. Refining breast cancer genetic risk and biology through multi-ancestry fine-mapping analyses of 192 risk regions. Nat. Genet. 57, 80–87 https://doi.org/10.1038/s41588-024-02031-y (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Jia, G. et al. Genome-wide association analyses of breast cancer in women of African ancestry identify new susceptibility loci and improve risk prediction. Nat. Genet. 56, 819–826 https://doi.org/10.1038/s41588-024-01736-4 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Hughes, E. et al. Development and validation of a breast cancer polygenic risk score on the basis of genetic ancestry composition. JCO Precis. Oncol. 6, e2200084 https://doi.org/10.1200/PO.22.00084 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  127. Ping, J. et al. Using genome and transcriptome data from African-ancestry female participants to identify putative breast cancer susceptibility genes. Nat. Commun. 15, 3718 https://doi.org/10.1038/s41467-024-47650-5 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Li, J. L. et al. Improved polygenic risk prediction models for breast cancer subtypes in women of African ancestry. Nat. Genet. 58, 560–569 https://doi.org/10.1038/s41588-026-02501-5 (2026).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Sun, Y. et al. Polygenic risk scores for breast cancer among African American women with high risk. JAMA Netw. Open 9, e2619285 https://doi.org/10.1001/jamanetworkopen.2026.19285 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  130. Franco, I. et al. Genomic characterization of aggressive breast cancer in younger women. Ann. Surg. Oncol. 30, 7569–7578 https://doi.org/10.1245/s10434-023-14080-4 (2023).

    Article  PubMed  Google Scholar 

  131. Scott, L. C., Mobley, L. R., Kuo, T. M. & Il’yasova, D. Update on triple-negative breast cancer disparities for the United States: a population-based study from the United States Cancer Statistics database, 2010 through 2014. Cancer 125, 3412–3417 https://doi.org/10.1002/cncr.32207 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  132. Dietze, E. C., Sistrunk, C., Miranda-Carboni, G., O’Regan, R. & Seewaldt, V. L. Triple-negative breast cancer in African-American women: disparities versus biology. Nat. Rev. Cancer 15, 248–254 https://doi.org/10.1038/nrc3896 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Ein Gal, S., Mathis, S., Pathak, B. & Frenkel, M. The role of integrative oncology in patients affected by triple negative breast cancer. Curr. Oncol. Rep. 27, 1144–1154 https://doi.org/10.1007/s11912-025-01711-0 (2025).

    Article  PubMed  Google Scholar 

  134. Newman, L. A. et al. Hereditary susceptibility for triple negative breast cancer associated with western sub-Saharan African ancestry: results from an international surgical breast cancer collaborative. Ann. Surg. 270, 484–492 https://doi.org/10.1097/SLA.0000000000003459 (2019).

    Article  PubMed  Google Scholar 

  135. Loibl, S., Poortmans, P., Morrow, M., Denkert, C. & Curigliano, G. Breast cancer. Lancet 397, 1750–1769 https://doi.org/10.1016/S0140-6736(20)32381-3 (2021).

    Article  CAS  PubMed  Google Scholar 

  136. Sanchez-Covarrubias, A. P. et al. Reproductive risk factor patterns in Caribbean women with breast cancer across 4 generations. JAMA Netw. Open 7, e2438091 https://doi.org/10.1001/jamanetworkopen.2024.38091 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  137. Song, Z. et al. Association of reproductive and menstrual factors with the risk of breast cancer in women: a population-based study. BMC Cancer 25, 1621 https://doi.org/10.1186/s12885-025-15048-1 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Morch, L. S. et al. Contemporary hormonal contraception and the risk of breast cancer. N. Engl. J. Med. 377, 2228–2239 https://doi.org/10.1056/NEJMoa1700732 (2017).

    Article  PubMed  Google Scholar 

  139. Hadizadeh, F., Koteci, A., Karlsson, T., Ek, W. E. & Johansson, A. Hormonal contraceptive formulations and breast cancer risk in adolescents and premenopausal women. JAMA Oncol. 11, 1497–1506 https://doi.org/10.1001/jamaoncol.2025.4480 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  140. Gompel, A. & Simcock, R. Menopausal hormone treatment and breast cancer. Lancet Diabetes Endocrinol. 14, 259–274 https://doi.org/10.1016/S2213-8587(25)00394-8 (2026).

    Article  PubMed  Google Scholar 

  141. McDonald, J. A. et al. Pregnancy-related factors and breast cancer risk for women across a range of familial risk. JAMA Netw. Open 7, e2427441 https://doi.org/10.1001/jamanetworkopen.2024.27441 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  142. Anderson, K. N., Schwab, R. B. & Martinez, M. E. Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res. Treat. 144, 1–10 https://doi.org/10.1007/s10549-014-2852-7 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  143. Nichols, H. B. et al. Breast cancer risk after recent childbirth: a pooled analysis of 15 prospective studies. Ann. Intern. Med. 170, 22–30 https://doi.org/10.7326/M18-1323 (2019).

    Article  PubMed  Google Scholar 

  144. Islami, F. et al. Breastfeeding and breast cancer risk by receptor status — a systematic review and meta-analysis. Ann. Oncol. 26, 2398–2407 https://doi.org/10.1093/annonc/mdv379 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Ma, H. et al. Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. Breast Cancer Res. 19, 6 https://doi.org/10.1186/s13058-016-0799-9 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  146. Virassamy, B. et al. Parity and lactation induce T-cell-mediated breast cancer protection. Nature 649, 449–459 https://doi.org/10.1038/s41586-025-09713-5 (2026).

    Article  CAS  PubMed  Google Scholar 

  147. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347, 1713–1727 https://doi.org/10.1016/s0140-6736(96)90806-5 (1996).

    Article  Google Scholar 

  148. Ferguson, D., Fraker, J., Sahni, S., Vegunta, S. & David, P. S. Breast cancer risk in peri- and postmenopausal women with a history of hormonal contraceptive use: a narrative review. Maturitas 208, 108898 https://doi.org/10.1016/j.maturitas.2026.108898 (2026).

    Article  PubMed  Google Scholar 

  149. Rezoug, Z. et al. Universal genetic testing for newly diagnosed invasive breast cancer. JAMA Netw. Open 7, e2431427 https://doi.org/10.1001/jamanetworkopen.2024.31427 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  150. Yadav, S. et al. Landscape of somatic genetic alterations and PAM50 intrinsic subtypes in breast cancer associated with germline pathogenic variants in DNA-repair genes. J. Natl Cancer Inst. https://doi.org/10.1093/jnci/djag070 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  151. Villarreal-Garza, C. et al. Breast cancer in young women in Latin America: an unmet, growing burden. Oncologist 18, 1298–1306 https://doi.org/10.1634/theoncologist.2013-0321 (2013).

    Article  PubMed  PubMed Central  Google Scholar 

  152. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 https://doi.org/10.3322/caac.21660 (2021).

    Article  CAS  PubMed  Google Scholar 

  153. Effiong, M. E. et al. Age-specific patterns of breast cancer in Nigerian women unraveled through histological analysis. Sci. Rep. 16, 128 https://doi.org/10.1038/s41598-025-28685-0 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Williams, L. A., Olshan, A. F., Tse, C. K., Bell, M. E. & Troester, M. A. Alcohol intake and invasive breast cancer risk by molecular subtype and race in the Carolina Breast Cancer Study. Cancer Causes Control. 27, 259–269 https://doi.org/10.1007/s10552-015-0703-4 (2016).

    Article  PubMed  Google Scholar 

  155. Sudan, S. K. et al. Obesity and early-onset breast cancer and specific molecular subtype diagnosis in Black and white women: NIMHD Social Epigenomics Program. JAMA Netw. Open 7, e2421846 https://doi.org/10.1001/jamanetworkopen.2024.21846 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  156. Williams, L. A. et al. Alcohol intake and breast cancer risk in African American women from the AMBER Consortium. Cancer Epidemiol. Biomarkers Prev. 26, 787–794 https://doi.org/10.1158/1055-9965.EPI-16-0792 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  157. Premenopausal Breast Cancer Collaborative Group et al. Association of body mass index and age with subsequent breast cancer risk in premenopausal women. JAMA Oncol. 4, e181771 https://doi.org/10.1001/jamaoncol.2018.1771 (2018).

    Article  Google Scholar 

  158. van den Brandt, P. A. et al. Body size and weight change over adulthood and risk of breast cancer by menopausal and hormone receptor status: a pooled analysis of 20 prospective cohort studies. Eur. J. Epidemiol. 36, 37–55 https://doi.org/10.1007/s10654-020-00688-3 (2021).

    Article  CAS  PubMed  Google Scholar 

  159. Fang, Z. & Giovannucci, E. L. The timing of adiposity and changes in the life course on the risk of cancer. Cancer Metastasis Rev. 41, 471–489 https://doi.org/10.1007/s10555-022-10054-2 (2022).

    Article  PubMed  Google Scholar 

  160. Sohi, I. et al. Alcoholic beverage consumption and female breast cancer risk: a systematic review and meta-analysis of prospective cohort studies. Alcohol. Clin. Exp. Res. 48, 2222–2241 https://doi.org/10.1111/acer.15493 (2024).

    Article  CAS  Google Scholar 

  161. Morford, K. L., Tetrault, J. M. & O’Connor, P. G. Alcohol and cancer risk. JAMA 334, 908–909 https://doi.org/10.1001/jama.2025.11229 (2025).

    Article  PubMed  Google Scholar 

  162. Chen, W. Y., Rosner, B., Hankinson, S. E., Colditz, G. A. & Willett, W. C. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA 306, 1884–1890 https://doi.org/10.1001/jama.2011.1590 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  163. Timmins, I. R. et al. International pooled analysis of leisure-time physical activity and premenopausal breast cancer in women from 19 cohorts. J. Clin. Oncol. 42, 927–939 https://doi.org/10.1200/JCO.23.01101 (2024).

    Article  CAS  PubMed  Google Scholar 

  164. Parrish, M., Traugh, N., Seraj, M. & Kuperwasser, C. Field cancerization, accelerated aging, and immunosuppression: the rapid rise of hormone-sensitive and early-onset breast cancer. NPJ Breast Cancer 11, 128 https://doi.org/10.1038/s41523-025-00840-w (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  165. Zeinomar, N., Oskar, S., Kehm, R. D., Sahebzeda, S. & Terry, M. B. Environmental exposures and breast cancer risk in the context of underlying susceptibility: a systematic review of the epidemiological literature. Env. Res. 187, 109346 https://doi.org/10.1016/j.envres.2020.109346 (2020).

    Article  CAS  Google Scholar 

  166. Terry, M. B. et al. Environmental exposures during windows of susceptibility for breast cancer: a framework for prevention research. Breast Cancer Res. 21, 96 https://doi.org/10.1186/s13058-019-1168-2 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  167. Ekenga, C. C., Parks, C. G. & Sandler, D. P. Chemical exposures in the workplace and breast cancer risk: a prospective cohort study. Int. J. Cancer 137, 1765–1774 https://doi.org/10.1002/ijc.29545 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Le Provost, B. et al. Residential exposure to ambient fine particulate matter (PM2.5) and nitrogen dioxide (NO2) and incident breast cancer among young women in Ontario, Canada. Cancer Epidemiol. 92, 102606 https://doi.org/10.1016/j.canep.2024.102606 (2024).

    Article  PubMed  Google Scholar 

  169. Gormley, M. et al. A Society-to-Cells approach to evaluating multilevel and interrelated drivers of breast cancer disparities in Black women. NPJ Breast Cancer 11, 90 https://doi.org/10.1038/s41523-025-00812-0 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  170. Barnard, M. E. et al. Associations between social drivers of health and breast cancer stage at diagnosis among U.S. Black women. NPJ Breast Cancer 11, 85 https://doi.org/10.1038/s41523-025-00804-0 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  171. Kehm, R. D., Lloyd, S. E., Burke, K. R. & Terry, M. B. Advancing environmental epidemiologic methods to confront the cancer burden. Am. J. Epidemiol. 194, 195–207 https://doi.org/10.1093/aje/kwae175 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  172. Duboeuf, M. et al. Long-term exposure to air pollution at residential and workplace addresses and breast cancer risk: a case-control study nested in the French E3N-Generations cohort from 1990 to 2011. Eur. J. Cancer 210, 114293 https://doi.org/10.1016/j.ejca.2024.114293 (2024).

    Article  CAS  PubMed  Google Scholar 

  173. Miller, C. A. et al. Cancer prevention in context: interplay of perceived discrimination, neighborhood deprivation, and cancer-related risk and protective factors. J. Natl Cancer Inst. 118, 1715–1723 https://doi.org/10.1093/jnci/djag101 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  174. Goel, N. et al. Structural racism and breast cancer-specific survival: impact of economic and racial residential segregation. Ann. Surg. 275, 776–783 https://doi.org/10.1097/SLA.0000000000005375 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  175. Plascak, J. J. & Bauer, C. X. Uptake and utility of geographically sensitive neighborhoodwide association studies of cancer. JAMA Netw. Open 9, e2558191 https://doi.org/10.1001/jamanetworkopen.2025.58191 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  176. Peiris, M. N. et al. Breast cancer inequities: the intersectional role of social epidemiology and tumor biology. Cancer Causes Control 37, 57 https://doi.org/10.1007/s10552-026-02138-z (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  177. Falcone, M. et al. Impact of structural racism and social determinants of health on disparities in breast cancer mortality. Cancer Res. 84, 3924–3935 https://doi.org/10.1158/0008-5472.CAN-24-1359 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  178. Coughlin, S. S. Social determinants of breast cancer risk, stage, and survival. Breast Cancer Res. Treat. 177, 537–548 https://doi.org/10.1007/s10549-019-05340-7 (2019).

    Article  PubMed  Google Scholar 

  179. Goel, N., Hernandez, A. & Cole, S. W. Social genomic determinants of health: understanding the molecular pathways by which neighborhood disadvantage affects cancer outcomes. J. Clin. Oncol. 42, 3618–3627 https://doi.org/10.1200/JCO.23.02780 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  180. Maas, P. et al. Breast cancer risk from modifiable and nonmodifiable risk factors among white women in the United States. JAMA Oncol. 2, 1295–1302 https://doi.org/10.1001/jamaoncol.2016.1025 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  181. Tamimi, R. M. et al. Population attributable risk of modifiable and nonmodifiable breast cancer risk factors in postmenopausal breast cancer. Am. J. Epidemiol. 184, 884–893 https://doi.org/10.1093/aje/kww145 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  182. Britt, K. L., Cuzick, J. & Phillips, K. A. Key steps for effective breast cancer prevention. Nat. Rev. Cancer 20, 417–436 https://doi.org/10.1038/s41568-020-0266-x (2020).

    Article  CAS  PubMed  Google Scholar 

  183. Brown, K. A. Metabolic pathways in obesity-related breast cancer. Nat. Rev. Endocrinol. 17, 350–363 https://doi.org/10.1038/s41574-021-00487-0 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  184. Naaman, S. C., Shen, S., Zeytinoglu, M. & Iyengar, N. M. Obesity and breast cancer risk: the oncogenic implications of metabolic dysregulation. J. Clin. Endocrinol. Metab. 107, 2154–2166 https://doi.org/10.1210/clinem/dgac241 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  185. Guo, W., Fensom, G. K., Reeves, G. K. & Key, T. J. Physical activity and breast cancer risk: results from the UK Biobank prospective cohort. Br. J. Cancer 122, 726–732 https://doi.org/10.1038/s41416-019-0700-6 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  186. Papadimitriou, N. et al. Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nat. Commun. 11, 597 https://doi.org/10.1038/s41467-020-14389-8 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  187. Kotsopoulos, J. et al. Parity, breastfeeding, and the risk of early-onset breast cancer in women with a BRCA1 pathogenic variant. Br. J. Cancer 133, 104–110 https://doi.org/10.1038/s41416-025-03029-x (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  188. Nelson, H. D. et al. Patient navigation services for breast and cervical cancer screening and follow-up: a meta-analysis. JAMA Intern. Med. 185, 976–985 https://doi.org/10.1001/jamainternmed.2025.1590 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  189. Qaseem, A. et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (version 2). Ann. Intern. Med. https://doi.org/10.7326/ANNALS-25-05116 (2026).

    Article  PubMed  Google Scholar 

  190. Hu, X. et al. Presentation and characteristics of breast cancer in young women under age 40. Breast Cancer Res. Treat. 186, 209–217 https://doi.org/10.1007/s10549-020-06000-x (2021).

    Article  PubMed  Google Scholar 

  191. Holt, D. B. Breast density masking and the need for precision screening. JAMA 335, 1385–1386 https://doi.org/10.1001/jama.2026.2443 (2026).

    Article  PubMed  Google Scholar 

  192. Kim, S. H. et al. Mammographic density as a predictor of invasive breast cancer and ductal carcinoma in situ in over six million South Korean women. Breast Cancer Res. Treat. 211, 341–350 https://doi.org/10.1007/s10549-025-07648-z (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  193. Perera, D. et al. The distribution of breast density in women aged 18 years and older. Breast Cancer Res. Treat. 205, 521–531 https://doi.org/10.1007/s10549-024-07269-y (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  194. Dreher, N. et al. A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer. Breast Cancer Res. Treat. 191, 623–629 https://doi.org/10.1007/s10549-021-06451-w (2022).

    Article  PubMed  Google Scholar 

  195. Zhang, Y. et al. Incidence and risk factors of interval and screen-detected breast cancer. JAMA Oncol. 11, 519–527 https://doi.org/10.1001/jamaoncol.2025.0167 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  196. Trentham-Dietz, A. et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA 331, 1947–1960 https://doi.org/10.1001/jama.2023.24766 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  197. Kerlikowske, K., Esserman, L. & Tice, J. A. Screening mammography for 40-year-old women-whose decision? JAMA Intern. Med. 184, 1281–1282 https://doi.org/10.1001/jamainternmed.2024.4277 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  198. Hartmann, L. C., Degnim, A. C., Santen, R. J., Dupont, W. D. & Ghosh, K. Atypical hyperplasia of the breast-risk assessment and management options. N. Engl. J. Med. 372, 78–89 https://doi.org/10.1056/NEJMsr1407164 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  199. Baker, J. et al. Atypical ductal or lobular hyperplasia, lobular carcinoma in-situ, flat epithelial atypia, and future risk of developing breast cancer: systematic review and meta-analysis. Breast 78, 103807 https://doi.org/10.1016/j.breast.2024.103807 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  200. Menes, T. S. et al. Subsequent breast cancer risk following diagnosis of atypical ductal hyperplasia on needle biopsy. JAMA Oncol. 3, 36–41 https://doi.org/10.1001/jamaoncol.2016.3022 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  201. Li, S. et al. Segregation analysis of 17,425 population-based breast cancer families: evidence for genetic susceptibility and risk prediction. Am. J. Hum. Genet. 109, 1777–1788 https://doi.org/10.1016/j.ajhg.2022.09.006 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  202. Wendt, C. & Margolin, S. Identifying breast cancer susceptibility genes - a review of the genetic background in familial breast cancer. Acta Oncol. 58, 135–146 https://doi.org/10.1080/0284186X.2018.1529428 (2019).

    Article  CAS  PubMed  Google Scholar 

  203. Dossa, F. et al. Breast and ovarian cancer among individuals undergoing BRCA1 and BRCA2 testing. JAMA Netw. Open 9, e2626334 https://doi.org/10.1001/jamanetworkopen.2026.26334 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  204. Makhnoon, S. et al. Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes. Cancer 127, 3605–3613 https://doi.org/10.1002/cncr.33668 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  205. Botty van den Bruele, A. & Weiss, A. Society of Surgical Oncology Breast Disease Site Work Group. Updated guidelines on when to consider germline testing for patients with breast cancer. Ann. Surg. Oncol. 31, 5479–5482 https://doi.org/10.1245/s10434-024-15638-6 (2024).

    Article  PubMed  Google Scholar 

  206. Koldehoff, A. et al. Cost-effectiveness of targeted genetic testing for breast and ovarian cancer: a systematic review. Value Health 24, 303–312 https://doi.org/10.1016/j.jval.2020.09.016 (2021).

    Article  PubMed  Google Scholar 

  207. Berliner, J. L., Cummings, S. A., Boldt Burnett, B. & Ricker, C. N. Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes —practice resource of the National Society of Genetic Counselors. J. Genet. Couns. 30, 342–360 https://doi.org/10.1002/jgc4.1374 (2021).

    Article  PubMed  Google Scholar 

  208. Terry, M. B. et al. 10-year performance of four models of breast cancer risk: a validation study. Lancet Oncol. 20, 504–517 https://doi.org/10.1016/S1470-2045(18)30902-1 (2019).

    Article  PubMed  Google Scholar 

  209. Pal Choudhury, P. et al. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. Breast Cancer Res. 23, 22 https://doi.org/10.1186/s13058-021-01399-7 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  210. Aliberti, G. M., Weinstein, A. R. & Schonberg, M. A. When risk scores meet mammography-navigating supplemental screening decisions. JAMA Intern. Med. 186, 927–928 https://doi.org/10.1001/jamainternmed.2026.2420 (2026).

    Article  PubMed  Google Scholar 

  211. National Comprehensive Cancer Network. Breast Cancer Screening and Diagnosis (NCCN, 2026).

  212. National Comprehensive Cancer Network. Breast Cancer Risk Reduction (NCCN, 2026).

  213. Saslow, D. et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J. Clin. 57, 75–89 https://doi.org/10.3322/canjclin.57.2.75 (2007).

    Article  PubMed  Google Scholar 

  214. Petitjean, C. et al. Evaluating the performance of the breast and ovarian analysis of disease incidence algorithm model in predicting 10-year breast cancer risks in UK Biobank. J. Natl Cancer Inst. 117, 948–958 https://doi.org/10.1093/jnci/djae335 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  215. Mavaddat, N. et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am. J. Hum. Genet. 104, 21–34 https://doi.org/10.1016/j.ajhg.2018.11.002 (2019).

    Article  CAS  PubMed  Google Scholar 

  216. Yang, X., Kar, S., Antoniou, A. C. & Pharoah, P. D. P. Polygenic scores in cancer. Nat. Rev. Cancer 23, 619–630 https://doi.org/10.1038/s41568-023-00599-x (2023).

    Article  CAS  PubMed  Google Scholar 

  217. Yang, X. et al. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study. J. Med. Genet. 59, 1196–1205 https://doi.org/10.1136/jmg-2022-108806 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  218. Hovhannisyan, M. et al. Population-specific validation and comparison of the performance of 77- and 313-variant polygenic risk scores for breast cancer risk prediction. Cancer 130, 2978–2987 https://doi.org/10.1002/cncr.35337 (2024).

    Article  PubMed  Google Scholar 

  219. Esserman, L. J. et al. Risk-based vs annual breast cancer screening: the WISDOM randomized clinical trial. JAMA https://doi.org/10.1001/jama.2025.24784 (2025).

    Article  Google Scholar 

  220. Pashayan, N. et al. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nat. Rev. Clin. Oncol. 17, 687–705 https://doi.org/10.1038/s41571-020-0388-9 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  221. Du, Z. et al. Evaluating polygenic risk scores for breast cancer in women of African ancestry. J. Natl Cancer Inst. 113, 1168–1176 https://doi.org/10.1093/jnci/djab050 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  222. Stutzin Donoso, F. et al. CanRisk-GP protocol: a feasibility study of incorporating proactive multifactorial breast cancer risk assessment into general practice. PLoS ONE 20, e0336902 https://doi.org/10.1371/journal.pone.0336902 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  223. Hunter, D. J. & Inouye, M. Clinical uses of common genetic variants associated with common diseases. N. Engl. J. Med. 395, 1206–1217 https://doi.org/10.1056/NEJMra2413201 (2026).

    Article  PubMed  Google Scholar 

  224. Tsoulaki, O. et al. Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice. Br. J. Cancer 130, 2027–2036 https://doi.org/10.1038/s41416-024-02733-4 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  225. Gu, M., Zhang, W. Z., Fitzgerald, R. C., Frankell, A. M. & Vassiliou, G. S. Harnessing genomics for early cancer detection, risk stratification and prevention. Nat. Genet. 58, 704–716 https://doi.org/10.1038/s41588-026-02505-1 (2026).

    Article  CAS  PubMed  Google Scholar 

  226. Esserman, L. et al. The WISDOM study: a new approach to screening can and should be tested. Breast Cancer Res. Treat. 189, 593–598 https://doi.org/10.1007/s10549-021-06346-w (2021).

    Article  PubMed  Google Scholar 

  227. Fiscalini, A. et al. WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design. npj Breast Cancer 12, 108 https://doi.org/10.1038/s41523-026-00952-x (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  228. Leggat-Barr, K. et al. Early ascertainment of breast cancer diagnoses comparing self-reported questionnaires and electronic health record data warehouse: the WISDOM Study. JCO Clin. Cancer Inf. 7, e2300019 https://doi.org/10.1200/CCI.23.00019 (2023).

    Article  Google Scholar 

  229. Lubinski, J. et al. MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations. JAMA Oncol. 10, 493–499 https://doi.org/10.1001/jamaoncol.2023.6944 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  230. Lee, T. C., Reyna, C., Shaughnessy, E. & Lewis, J. D. Screening of populations at high risk for breast cancer. J. Surg. Oncol. 120, 820–830 https://doi.org/10.1002/jso.25611 (2019).

    Article  PubMed  Google Scholar 

  231. Whitaker, K. D., Sheth, D. & Olopade, O. I. Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet? Breast Cancer Res. Treat. 183, 243–250 https://doi.org/10.1007/s10549-020-05759-3 (2020).

    Article  CAS  PubMed  Google Scholar 

  232. Bick, U. et al. High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. Breast Cancer Res. Treat. 175, 217–228 https://doi.org/10.1007/s10549-019-05152-9 (2019).

    Article  PubMed  Google Scholar 

  233. Expert Panel on Breast Imaging ACR Appropriateness Criteria® female breast cancer screening: 2025 update. J. Am. Coll. Radiol. 22, S508–S530 https://doi.org/10.1016/j.jacr.2025.08.044 (2025).

    Article  Google Scholar 

  234. Cornell, L. F. Comparison of high-risk breast cancer screenings with concurrent versus staggered breast MRI and mammogram schedules. J. Clin. Med. 15, 4239 https://doi.org/10.3390/jcm15114239 (2026).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  235. Cai, Y. et al. A systematic review of recommendations on screening strategies for breast cancer due to hereditary predisposition: who, when, and how. Cancer Med. 10, 3437–3448 https://doi.org/10.1002/cam4.3898 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  236. Saadatmand, S. et al. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial. Lancet Oncol. 20, 1136–1147 https://doi.org/10.1016/S1470-2045(19)30275-X (2019).

    Article  PubMed  Google Scholar 

  237. Tosteson, A. N. A. et al. Outcomes of density-targeted supplemental breast magnetic resonance imaging screening by breast cancer risk: long-term health and economic considerations. Ann. Intern. Med. 179, 486–496 https://doi.org/10.7326/ANNALS-25-00792 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  238. Miglioretti, D. L. et al. Association between false-positive results and return to screening mammography in the breast cancer surveillance consortium cohort. Ann. Intern. Med. 177, 1297–1307 https://doi.org/10.7326/M24-0123 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  239. Nelson, H. D. et al. Harms of breast cancer screening: systematic review to update the 2009 U.S. Preventive Services Task Force Recommendation. Ann. Intern. Med. 164, 256–267 https://doi.org/10.7326/M15-0970 (2016).

    Article  PubMed  Google Scholar 

  240. Qaseem, A. et al. Screening for breast cancer in average-risk women: a guidance statement from the American College of Physicians. Ann. Intern. Med. 170, 547–560 https://doi.org/10.7326/M18-2147 (2019).

    Article  PubMed  Google Scholar 

  241. Boucheron, P. et al. Measuring the WHO Global Breast Cancer Initiative Pillars’ key performance indicators in sub-Saharan Africa: experience in the African Breast Cancer-Disparities in Outcomes hospital-based cohort study. EClinicalMedicine 81, 103104 https://doi.org/10.1016/j.eclinm.2025.103104 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  242. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, Esophageal, and Gastric (NCCN, 2026).

  243. Esserman, L. J., Study, W. & Athena, I. The WISDOM Study: breaking the deadlock in the breast cancer screening debate. NPJ Breast Cancer 3, 34 https://doi.org/10.1038/s41523-017-0035-5 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  244. Wang, T. et al. Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study. NPJ Breast Cancer 10, 90 https://doi.org/10.1038/s41523-024-00681-z (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  245. Duggan, C. et al. National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis. Lancet Oncol. 22, 1632–1642 https://doi.org/10.1016/S1470-2045(21)00462-9 (2021).

    Article  PubMed  Google Scholar 

  246. Agbedinu, K. et al. A scoping review on barriers to cancer diagnosis and care in low- and middle-income countries. Cancer Epidemiol. Biomarkers Prev. 34, 1066–1073 https://doi.org/10.1158/1055-9965.EPI-25-0120 (2025).

    Article  PubMed  Google Scholar 

  247. Loizidis, S., Stanciu, M. A. & Ignatiadis, M. Liquid biopsy in breast cancer: promises and challenges. Curr. Opin. Oncol. 37, 512–521 https://doi.org/10.1097/CCO.0000000000001168 (2025).

    Article  CAS  PubMed  Google Scholar 

  248. Qiu, P. et al. Advancements in liquid biopsy for breast cancer: molecular biomarkers and clinical applications. Cancer Treat. Rev. 139, 102979 https://doi.org/10.1016/j.ctrv.2025.102979 (2025).

    Article  CAS  PubMed  Google Scholar 

  249. Lin, X. et al. Circulating tumor DNA in breast cancer: from technological foundation to clinical implementation. Cancer Treat. Rev. 144, 103108 https://doi.org/10.1016/j.ctrv.2026.103108 (2026).

    Article  CAS  PubMed  Google Scholar 

  250. Wood, M. E. et al. Performance of multiple multi-cancer detection tests using a large independent reference set (Alliance A212102). J. Natl Cancer Inst. 118, 730–736 https://doi.org/10.1093/jnci/djag001 (2026).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  251. Garcia-Murillas, I. et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol. 5, 1473–1478 https://doi.org/10.1001/jamaoncol.2019.1838 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  252. Sasieni, P. et al. Effect of screening with multicancer early-detection test on late-stage cancer diagnosis. N. Engl. J. Med. 395, 1374–1386 https://doi.org/10.1056/NEJMoa2505723 (2026).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  253. Bermudez-Guzman, L. Signal-to-care gap in multicancer early detection. JAMA Intern. Med. 186, 1193–1194 https://doi.org/10.1001/jamainternmed.2026.2744 (2026).

    Article  PubMed  Google Scholar 

  254. Snead, C. M., Zheng, D., Ngo-Metzger, Q. & Gould, M. K. Multicancer detection assays: promise and potential harms of a novel cancer screening tool. Perm. J. 30, 1–7 https://doi.org/10.7812/TPP/25.075 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  255. Schlam, I., Tolaney, S. M., Lin, N. U., Parsons, H. & Morganti, S. Circulating tumor DNA in early breast cancer: a review. JAMA Oncol. 12, 773–784 https://doi.org/10.1001/jamaoncol.2026.1465 (2026).

    Article  PubMed  Google Scholar 

  256. Smith, R. A., Cokkinides, V. & Brawley, O. W. Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues. CA Cancer J. Clin. 58, 161–179 https://doi.org/10.3322/CA.2007.0017 (2008).

    Article  PubMed  Google Scholar 

  257. Chavez-Yenter, D. et al. Association of disparities in family history and family cancer history in the electronic health record with sex, race, Hispanic or Latino ethnicity, and language preference in 2 large US health care systems. JAMA Netw. Open 5, e2234574 https://doi.org/10.1001/jamanetworkopen.2022.34574 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  258. Record, S. M. et al. Breast cancer risk assessment and screening practices reported via an online survey. Ann. Surg. Oncol. 30, 6219–6229 https://doi.org/10.1245/s10434-023-13903-8 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  259. McGarrigle, S. A. et al. Risk prediction models for familial breast cancer. Cochrane Database Syst. Rev. 6, CD013185 https://doi.org/10.1002/14651858.CD013185.pub2 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  260. Menes, T. S., Sella, T. & Chodick, G. Time to cancer diagnosis in young women presenting to surgeons with breast-related symptoms: a population-based cohort study. J. Womens Health 29, 493–502 https://doi.org/10.1089/jwh.2019.7967 (2020).

    Article  Google Scholar 

  261. Ruddy, K. J. et al. Breast cancer presentation and diagnostic delays in young women. Cancer 120, 20–25 https://doi.org/10.1002/cncr.28287 (2014).

    Article  PubMed  Google Scholar 

  262. Webber, C., Whitehead, M., Eisen, A., Holloway, C. M. B. & Groome, P. A. Factors associated with waiting time to breast cancer diagnosis among symptomatic breast cancer patients: a population-based study from Ontario, Canada. Breast Cancer Res. Treat. 187, 225–235 https://doi.org/10.1007/s10549-020-06051-0 (2021).

    Article  PubMed  Google Scholar 

  263. Ulanday, K. T. et al. Cancers missed, women dismissed yet persist: natural language processing of online forums. Breast Cancer Res. 27, 78 https://doi.org/10.1186/s13058-025-01985-z (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  264. Miller, K. D. et al. Cancer statistics for adolescents and young adults, 2020. CA Cancer J. Clin. 70, 443–459 https://doi.org/10.3322/caac.21637 (2020).

    Article  PubMed  Google Scholar 

  265. Expert Panel on Breast Imaging ACR Appropriateness Criteria® breast imaging during pregnancy. J. Am. Coll. Radiol. 22, S492–S507 https://doi.org/10.1016/j.jacr.2025.08.045 (2025).

    Article  Google Scholar 

  266. Fazeli, S., Sakala, M., Rakow-Penner, R. & Ojeda-Fournier, H. Cancer in pregnancy: breast cancer. Abdom. Radiol. 48, 1645–1662 https://doi.org/10.1007/s00261-023-03824-1 (2023).

    Article  Google Scholar 

  267. Harbeck, N. et al. Breast cancer. Nat. Rev. Dis. Primers 5, 66 https://doi.org/10.1038/s41572-019-0111-2 (2019).

    Article  PubMed  Google Scholar 

  268. Ribeiro, R. et al. Guidelines of the Brazilian Society of Surgical Oncology for anatomopathological, immunohistochemical, and molecular testing in female tumors. J. Surg. Oncol. 130, 882–895 https://doi.org/10.1002/jso.27717 (2024).

    Article  CAS  PubMed  Google Scholar 

  269. Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline Update. J. Clin. Oncol. 38, 1346–1366 https://doi.org/10.1200/JCO.19.02309 (2020).

    Article  PubMed  Google Scholar 

  270. Reissis, Y., Miller, B., Friebel, R. & Hargest, R. Where do delays occur? A systematic review of the barriers to early breast cancer diagnosis across South Africa’s health system. BMJ Open 16, e122056 https://doi.org/10.1136/bmjopen-2026-122056 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  271. Ngwa, W. et al. Cancer in sub-Saharan Africa: a Lancet Oncology Commission. Lancet Oncol. 23, e251–e312 https://doi.org/10.1016/S1470-2045(21)00720-8 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  272. Anderson, B. O., Duggan, C. & Scheel, J. R. Resource-appropriate evidence-based strategies to improve breast cancer outcomes in low- and middle-income countries guided by the Breast Health Global Initiative and Global Breast Cancer Initiative. J. Surg. Oncol. 128, 952–958 https://doi.org/10.1002/jso.27480 (2023).

    Article  PubMed  Google Scholar 

  273. Distelhorst, S. R. et al. Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014. Lancet Oncol. 16, e137–e147 https://doi.org/10.1016/S1470-2045(14)70457-7 (2015).

    Article  PubMed  Google Scholar 

  274. Ong, S. K. et al. Feasibility of monitoring Global Breast Cancer Initiative Framework key performance indicators in 21 Asian National Cancer Centers Alliance member countries. EClinicalMedicine 67, 102365 https://doi.org/10.1016/j.eclinm.2023.102365 (2024).

    Article  PubMed  Google Scholar 

  275. Ntekim, A. et al. Pragmatic clinical trial assessing response to neoadjuvant docetaxel and trastuzumab in Nigerian women with human epidermal growth factor receptor 2-positive breast cancer. JCO Glob. Oncol. 12, e2500287 https://doi.org/10.1200/GO-25-00287 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  276. Buzdar, A. U. et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 23, 3676–3685 https://doi.org/10.1200/JCO.2005.07.032 (2005).

    Article  CAS  PubMed  Google Scholar 

  277. Buzdar, A. U. et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin. Cancer Res. 13, 228–233 https://doi.org/10.1158/1078-0432.CCR-06-1345 (2007).

    Article  CAS  PubMed  Google Scholar 

  278. Meernik, C. et al. Material and psychological financial hardship related to employment disruption among female adolescent and young adult cancer survivors. Cancer 127, 137–148 https://doi.org/10.1002/cncr.33190 (2021).

    Article  PubMed  Google Scholar 

  279. Tangka, F. K. L. et al. Insurance coverage, employment status, and financial well-being of young women diagnosed with breast cancer. Cancer Epidemiol. Biomarkers Prev. 29, 616–624 https://doi.org/10.1158/1055-9965.EPI-19-0352 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  280. Myers, S. P. et al. Financial difficulty over time in young adults with breast cancer. JAMA Netw. Open 7, e2446091 https://doi.org/10.1001/jamanetworkopen.2024.46091 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  281. Di Giuseppe, G., Jetha, A., Pechlivanoglou, P. & Pole, J. D. Long-term dynamic financial impacts among adolescents and young adults with cancer: a longitudinal matched-cohort study. J. Clin. Oncol. 43, 2467–2478 https://doi.org/10.1200/JCO-24-02121 (2025).

    Article  PubMed  Google Scholar 

  282. Guzauskas, G. F. et al. Population genomic screening for three common hereditary conditions: a cost-effectiveness analysis. Ann. Intern. Med. 176, 585–595 https://doi.org/10.7326/M22-0846 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  283. Guo, F. et al. Cost-effectiveness of population-based multigene testing for breast and ovarian cancer prevention. JAMA Netw. Open 7, e2356078 https://doi.org/10.1001/jamanetworkopen.2023.56078 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  284. Myers, S. P. et al. Impact of age and treatment-related adverse events on financial toxicity among patients with breast cancer: a systematic review. J. Cancer Surviv. https://doi.org/10.1007/s11764-025-01881-7 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  285. Myers, S. P. et al. Treatment-related adverse events as a source of financial hardship in young adults with breast cancer: a qualitative study. Support. Care Cancer 33, 884 https://doi.org/10.1007/s00520-025-09887-8 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  286. Cherny, N. I. et al. ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update. Ann. Oncol. 36, 247–262 https://doi.org/10.1016/j.annonc.2024.12.005 (2025).

    Article  CAS  PubMed  Google Scholar 

  287. Trapani, D. & Murthy, S. S. Progress in global breast cancer control. Curr. Opin. Oncol. 37, 529–533 https://doi.org/10.1097/CCO.0000000000001163 (2025).

    Article  PubMed  Google Scholar 

  288. Barrios, C. et al. Barriers in access to oncology drugs - a global crisis. Nat. Rev. Clin. Oncol. 20, 7–15 https://doi.org/10.1038/s41571-022-00700-7 (2023).

    Article  CAS  PubMed  Google Scholar 

  289. Wilson, B. E. et al. Global cancer drug development — a report from the 2022 Accelerating Anticancer Agent Development and Validation Meeting. JCO Glob. Oncol. https://doi.org/10.1200/go.23.00294 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  290. Erfani, P. et al. Advancing global pharmacoequity in oncology. JAMA Oncol. 11, 55–59 https://doi.org/10.1001/jamaoncol.2024.5032 (2025).

    Article  PubMed  Google Scholar 

  291. Cavaleri, M. et al. A roadmap for fostering timely regulatory and ethics approvals of international clinical trials in support of global health research systems. Lancet Glob. Health 13, e769–e777 https://doi.org/10.1016/S2214-109X(24)00515-1 (2025).

    Article  CAS  PubMed  Google Scholar 

  292. Hickey, M. et al. Managing menopause after cancer. Lancet 403, 984–996 https://doi.org/10.1016/S0140-6736(23)02802-7 (2024).

    Article  CAS  PubMed  Google Scholar 

  293. Vo, J. B. et al. Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors. J. Natl Cancer Inst. 116, 1384–1394 https://doi.org/10.1093/jnci/djae107 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  294. Runowicz, C. D. et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. J. Clin. Oncol. 34, 611–635 https://doi.org/10.1200/JCO.2015.64.3809 (2016).

    Article  CAS  PubMed  Google Scholar 

  295. Vrancken Peeters, N. et al. Long-term health issues of adolescent and young adult breast cancer survivors. Clin. Breast Cancer 26, 200–207.e4 https://doi.org/10.1016/j.clbc.2025.10.009 (2026).

    Article  PubMed  Google Scholar 

  296. Rosenberg, S. M. et al. Association of breast cancer surgery with quality of life and psychosocial well-being in young breast cancer survivors. JAMA Surg. 155, 1035–1042 https://doi.org/10.1001/jamasurg.2020.3325 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  297. Albini, A., DeCensi, A., Cavalli, F. & Costa, A. Cancer prevention and interception: a new era for chemopreventive approaches. Clin. Cancer Res. 22, 4322–4327 https://doi.org/10.1158/1078-0432.CCR-16-0695 (2016).

    Article  CAS  PubMed  Google Scholar 

  298. Grieco, C., Pandya, T. & Swanton, C. Molecular cancer prevention: intercepting disease. Mol. Oncol. https://doi.org/10.1002/1878-0261.70258 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  299. Blondeaux, E. et al. Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study. Lancet Oncol. 26, 759–770 https://doi.org/10.1016/S1470-2045(25)00152-4 (2025).

    Article  CAS  PubMed  Google Scholar 

  300. US Preventive Services Task Force Medication use to reduce risk of breast cancer: US Preventive Services Task Force recommendation statement. JAMA 322, 857–867 https://doi.org/10.1001/jama.2019.11885 (2019).

    Article  Google Scholar 

  301. Visvanathan, K. et al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J. Clin. Oncol. 37, 3152–3165 https://doi.org/10.1200/JCO.19.01472 (2019).

    Article  CAS  PubMed  Google Scholar 

  302. Nakhlis, F. et al. American Society of Breast Surgeons, Society of Breast Imaging, and College of American Pathology 2026 guidelines for the management of proliferative lesions with atypia and lobular carcinoma in situ. JAMA Surg. 161, 1076–1083 https://doi.org/10.1001/jamasurg.2026.3552 (2026).

    Article  PubMed  Google Scholar 

  303. Leggat-Barr, K. et al. A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women’s health. Breast Cancer Res. Treat. 209, 1–14 https://doi.org/10.1007/s10549-024-07522-4 (2025).

    Article  PubMed  Google Scholar 

  304. Frey, M. K. et al. What happens in the long term: uptake of cancer surveillance and prevention strategies among at-risk relatives with pathogenic variants detected via cascade testing. Cancer 128, 4241–4250 https://doi.org/10.1002/cncr.34482 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  305. Dubsky, P. et al. BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs? NPJ Breast Cancer 10, 77 https://doi.org/10.1038/s41523-024-00686-8 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  306. Wang, Y., Malkin, D. & Lipkin, S. M. Future trends in cancer prevention and interception in cancer predisposition syndromes: leveraging insights from high-risk populations. Int. J. Cancer https://doi.org/10.1002/ijc.70674 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  307. Albini, A. et al. From combination early detection to multicancer testing: shifting cancer care toward proactive prevention and interception. Cancer Prev. Res. 18, 583–602 https://doi.org/10.1158/1940-6207.CAPR-24-0558 (2025).

    Article  CAS  Google Scholar 

  308. Fackenthal, J. D. et al. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int. J. Cancer 131, 1114–1123 https://doi.org/10.1002/ijc.27326 (2012).

    Article  CAS  PubMed  Google Scholar 

  309. Zhang, J. et al. Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Res. Treat. 134, 889–894 https://doi.org/10.1007/s10549-012-2136-z (2012).

    Article  CAS  PubMed  Google Scholar 

  310. Zheng, Y. et al. Inherited breast cancer in Nigerian women. J. Clin. Oncol. 36, 2820–2825 https://doi.org/10.1200/JCO.2018.78.3977 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  311. Ansari-Pour, N. et al. Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nat. Commun. 12, 6946 https://doi.org/10.1038/s41467-021-27079-w (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  312. Mugo, N. & Contino, G. Genomic landscapes of breast cancer in African populations: a systematic review. NPJ Breast Cancer 11, 91 https://doi.org/10.1038/s41523-025-00809-9 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  313. Guo, W. et al. Genetic and nongenetic risk factors for breast cancer risk estimation. JAMA Netw. Open 8, e255804 https://doi.org/10.1001/jamanetworkopen.2025.5804 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  314. Ashi, K. et al. Validation of the Nigerian breast cancer study model for predicting individual breast cancer risk in Cameroon and Uganda. Cancer Epidemiol. Biomarkers Prev. 32, 98–104 https://doi.org/10.1158/1055-9965.EPI-22-0869 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  315. Pitt, J. J. et al. Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nat. Commun. 9, 4181 https://doi.org/10.1038/s41467-018-06616-0 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  316. Mai, P. L. et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer 122, 3673–3681 https://doi.org/10.1002/cncr.30248 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  317. Marabelli, M., Cheng, S. C. & Parmigiani, G. Penetrance of ATM gene mutations in breast cancer: a meta-analysis of different measures of risk. Genet. Epidemiol. 40, 425–431 https://doi.org/10.1002/gepi.21971 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  318. Dhawan, A. et al. Cancer and overgrowth manifestations of PTEN hamartoma tumor syndrome: management recommendations from the International PHTS Consensus Guidelines Working Group. Clin. Cancer Res. 31, 1754–1765 https://doi.org/10.1158/1078-0432.Ccr-24-3819 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  319. Ryan, C. E. et al. Germline CDH1 variants and lifetime cancer risk. JAMA 332, 722–729 https://doi.org/10.1001/jama.2024.10852 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  320. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 13, 1141–1151 https://doi.org/10.1016/S1470-2045(12)70425-4 (2012).

    Article  Google Scholar 

  321. Jung, A. Y. et al. Distinct reproductive risk profiles for intrinsic-like breast cancer subtypes: pooled analysis of population-based studies. J. Natl Cancer Inst. 114, 1706–1719 https://doi.org/10.1093/jnci/djac117 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  322. Clavel-Chapelon, F. & Group, E. N. E. Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br. J. Cancer 86, 723–727 https://doi.org/10.1038/sj.bjc.6600124 (2002).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  323. Prince, C. et al. Assessing the causal and independent impact of parity-related reproductive factors on risk of breast cancer subtypes. BMC Med. 23, 530 https://doi.org/10.1186/s12916-025-04375-6 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  324. Lambertini, M. et al. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: a systematic review and meta-analysis of epidemiological studies. Cancer Treat. Rev. 49, 65–76 https://doi.org/10.1016/j.ctrv.2016.07.006 (2016).

    Article  PubMed  Google Scholar 

  325. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360, 187–195 https://doi.org/10.1016/S0140-6736(02)09454-0 (2002).

    Article  Google Scholar 

  326. Islami, F. et al. American Cancer Society’s report on the status of cancer disparities in the United States, 2023. CA Cancer J. Clin. 74, 136–166 https://doi.org/10.3322/caac.21812 (2024).

    Article  PubMed  Google Scholar 

  327. John, E. M. et al. Reproductive history, breast-feeding and risk of triple negative breast cancer: The Breast Cancer Etiology in Minorities (BEM) study. Int. J. Cancer 142, 2273–2285 https://doi.org/10.1002/ijc.31258 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  328. Fitzpatrick, D., Pirie, K., Reeves, G., Green, J. & Beral, V. Combined and progestagen-only hormonal contraceptives and breast cancer risk: a UK nested case-control study and meta-analysis. PLoS Med. 20, e1004188 https://doi.org/10.1371/journal.pmed.1004188 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  329. Niemeyer Hultstrand, J. et al. Hormonal contraception and risk of breast cancer and breast cancer in situ among Swedish women 15-34 years of age: a nationwide register-based study. Lancet Reg. Health Eur. 21, 100470 https://doi.org/10.1016/j.lanepe.2022.100470 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  330. Kawai, M., Malone, K. E., Tang, M. T. & Li, C. I. Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years. Cancer 120, 1548–1556 https://doi.org/10.1002/cncr.28601 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  331. Kawai, M., Malone, K. E., Tang, M. T. & Li, C. I. Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years. Cancer 120, 1026–1034 https://doi.org/10.1002/cncr.28402 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  332. National Cancer Institute. SEER*Stat Databases: SEER November 2025 Submission https://seer.cancer.gov/data-software/documentation/seerstat/nov2025/ (2026).

来源:Nature 健康护理主题 · nature.com